InxMed (Shanghai) Co., Ltd.

Quick facts

Phase 3 pipeline

• IN10018 in combination with D-1553 · Oncology
  IN10018 in combination with D-1553 represents a dual-targeted immunotherapy approach designed to enhance anti-tumor immune responses through complementary mechanisms.

Phase 2 pipeline

• IN10018

Phase 1 pipeline

• D1553
• IN10018（Ifebemtinib）
• IN10018 in combination with PLD
• IN10018 in combination with RNK08954

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• InxMed (Shanghai) Co., Ltd. portfolio CI brief
• InxMed (Shanghai) Co., Ltd. pipeline updates RSS